SINDER & QIX New Product Release Conference

Oct 28, 2022, the QIX (Japan) held an online conference with five animal protection product (for dogs/cats) on the live broadcast platform of Sinder, which is the sole agent in China.

Mr. Li, the president of Sinder

Mr. Yasumichi Ikutame, President of QIX, said in his online speech that QIX, as a premium brand of pet medical care in Japan, has covered more than 6,000 pet hospitals in Japan since the launch of pet health care products in 2009.

The cooperation between QIX and Sinder started a few years ago at the East-West China Small Animal Practitioners Conference, where both parties reached a consensus on the animal health sector and successfully achieved the launch of the first batch of animal health products (7 cat and dog categories) in China in 2021.

Mr. Yasumichi Ikutame

QIX and Sinder collaborated this time to launch products such as Hepatect and Neuro, which are hot sellers in Japan. Mr. Yasumichi Tanmoku is delighted with their successful launch and hopes that both parties will continue to focus on the development of animal health.

Mr. Muneyuki Ota, Director of QIX Corporation, shared the experience in Japan that more and more veterinary hospitals are increasing their demand for animal health products. In the past, vets tended to prescribe drugs for the treatment of animal diseases, but in recent years, there has been a rise in the use of supplements in combination with drugs, or alternating between supplements and drugs. Mr Ota believes that China is likely to join Japan in becoming a "pet family" society, where the prevention and treatment of pet diseases will become the norm, and the demand for pet health products from Chinese pet families and the animal health business will increase day by day.

The joint launch of new products by QIX and Sinder has received support and attention from all walks of life, and we have received encouragement from many outstanding partners.

Mr. Li Yi, Chairman of Chengdu Weidian, said that the seven products listed in Phase one had good market feedback and the five products in Phase two had distinctive features, which largely filled the gap in clinical applications and were remarkable.

Mr. Yang Meng, Chairman of Jilin Boailekang, spoke about his praise for QIX products, praising their excellent appearance. The market information verified that QIX health products are effective, affordable and have few competing products of the same type, and the sales and repurchase rates are extremely optimistic.

Mr. Han Haidong, the founder of Quzhou Haiyao, said that the Phase one product had been widely recognized in Zhejiang Province and he was looking forward to the smooth launch of the Phase two product.